The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity

BACKGROUND: The current vaccine against tuberculosis (TB), BCG, has failed to control TB worldwide and the protective efficacy is moreover limited to 10–15 years. A vaccine that could efficiently boost a BCG-induced immune response and thus prolong protective immunity would therefore have a signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Billeskov, Rolf, Elvang, Tara T., Andersen, Peter L., Dietrich, Jes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386939/
https://www.ncbi.nlm.nih.gov/pubmed/22768165
http://dx.doi.org/10.1371/journal.pone.0039909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386939/
https://www.ncbi.nlm.nih.gov/pubmed/22768165
http://dx.doi.org/10.1371/journal.pone.0039909

Ejemplares similares